| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.062 | 0.2 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.35 | 0.2 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.2 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |